Ro Khanna bought Artivion Inc (NYSE: AORT)
Ro Khanna (D-CA), a U.S. Representative, has disclosed 1 trade in Artivion Inc (AORT) since 2022, a single purchase, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Ro Khanna bought $1,001 - $15,000 of Artivion Inc (NYSE: AORT) on April 17, 2022. Since that trade, AORT is up +24.86% against the S&P 500 up +79.04%, an outperformance of -54.17%.
Data updated
Ro Khanna's AORT trades vs the price
AORT is up +24.86% since Ro Khanna bought on April 17, 2022, versus +79.04% for the S&P 500.
Performance since this trade
All Ro Khanna AORT trades
Ro Khanna & AORT trading FAQ
Is it legal for Ro Khanna to trade Artivion Inc (AORT) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Artivion Inc (AORT), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Ro Khanna buy AORT?
Ro Khanna disclosed a purchase of $1,001 - $15,000 of Artivion Inc (AORT) on April 17, 2022, according to public STOCK Act filings.
How has AORT performed since Ro Khanna's trade?
Since Ro Khanna bought AORT on April 17, 2022, the stock is up +24.86%, versus +79.04% for the S&P 500 over the same period, an outperformance of -54.17%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional AORT trades?
Quantellect tracks every disclosed congressional trade in Artivion Inc (AORT) on the Artivion Inc congressional trading page, which aggregates filings across all members of Congress.
Ro Khanna's AORT tradesAll congressional filings for Artivion IncRo Khanna's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.